Bradley Hise
Payments from drug & device makers
Across 104 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$229
- Medtronic$210
- Cequr Corporation$170
- Sequel Med Tech, LLC$163
- AstraZeneca$113
- Amgen$91
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,076100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 6 | $229 |
| Medtronic | 10 | $210 |
| Cequr Corporation | 2 | $170 |
| Sequel Med Tech, LLC | 7 | $163 |
| AstraZeneca | 5 | $113 |
| Amgen | 6 | $91 |
| Esperion Therapeutics, Inc. | 6 | $88 |
| Dexcom, Inc. | 5 | $80 |
| Bayer | 5 | $77 |
| Insulet Corporation | 4 | $75 |
| Boehringer Ingelheim | 4 | $70 |
| BETA Bionics, Inc. | 3 | $53 |
| Ascensia Diabetes Care US Inc. | 3 | $50 |
| Corcept Therapeutics | 2 | $48 |
| Antares Pharma, Inc. | 3 | $46 |
| Novartis | 3 | $46 |
| Lilly USA, LLC | 3 | $44 |
| Kyowa Kirin, Inc. | 3 | $43 |
| Tandem Diabetes Care, Inc. | 2 | $40 |
| Pfizer | 2 | $35 |
| Amryt Pharma Holdings Ltd | 2 | $34 |
| Radius Health, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Novo Nordisk | 2 | $24 |
| BD | 1 | $23 |
| Halozyme Inc | 1 | $19 |
| Chiesi USA, Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Merck | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Recordati_rare_diseases_inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$143
- AFREZZA$129
How this compares
$2,076 in reported general payments places this provider in the 90th percentile of 1,121 family providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 203 | $347,253 |
| MounjaroTirzepatide | 71 | $102,965 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 69 | $93,707 |
| JardianceEmpagliflozin | 56 | $81,887 |
| FarxigaDapagliflozin Propanediol | 39 | $53,297 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 155 | $32,167 |
| TrulicityDulaglutide | 18 | $31,860 |
| Humalog Kwikpen U-100Insulin Lispro | 43 | $23,708 |
| RybelsusSemaglutide | 11 | $18,626 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $17,343 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $15,995 |
| Bydureon BciseExenatide Microspheres | 19 | $15,931 |
| Novolog FlexpenInsulin Aspart | 48 | $15,063 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,447 |
| HumalogInsulin Lispro | 23 | $8,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $24 | $372,415230 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $44 | $143,217112 claims |
| Boehringer IngelheimJardiance | $70 | $81,88756 claims |
| AstraZenecaFarxiga | $113 | $53,29739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,121 family providers in Minnesota.
Other family in Edina
- Amy RedlonEdina$8K
- Cara HerrmannEdina$8K
- Carrie van OverbekeEdina$3K
- Tessa Kay KochEdina$2K
- Erin HewittMinnetonka$172K
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Crista WenischBurnsville$30K
- Kathleen FredellMinneapolis$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.